Joachim Drevs

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 846 citations

Immunology, Oral Administration, Pharmacotherapy +20

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Joachim Drevs, Ilse Hofmann, Harald Hugenschmidt et al. · PubMed · 2000 · 309 citations

Urology, Angiogenesis, Oncology +15

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger et al. · Journal of Clinical Oncology · 2007 · 302 citations

Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound

Felix Kratz, André Warnecke, Karin Scheuermann et al. · Journal of Medicinal Chemistry · 2002 · 271 citations

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

Beate Schultheis, Dirk Strumberg, Ansgar Santel et al. · Journal of Clinical Oncology · 2014 · 250 citations